cyclopropanesulfon-p-toluidide | 146475-56-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: cyclopropanesulfon-p-toluidide
• 英文别名: N-(p-tolyl)cyclopropanesulfonamide；N-(4-methylphenyl)cyclopropanesulfonamide
• CAS: 146475-56-1
• 化学式: C₁₀H₁₃NO₂S
• 分子量: 211.285
• InChiKey: KMYTXKRLNIGGQC-UHFFFAOYSA-N

物化性质

• 熔点：
  94.4-96.1 °C
• 沸点：
  343.4±35.0 °C(Predicted)
• 密度：
  1.28±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  54.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  对甲酚 在 potassium phosphate 、 tris-(dibenzylideneacetone)dipalladium(0) 、 potassium carbonate 、 2-二-叔丁膦基-2',4',6'-三异丙基联苯 作用下， 以 2-甲基-2-丁醇 、 乙腈 为溶剂， 反应 15.0h， 生成 cyclopropanesulfon-p-toluidide
  参考文献：
  名称：

  A General Method for Palladium-Catalyzed Reactions of Primary Sulfonamides with Aryl Nonaflates

  摘要：

  A general method for Pd-catalyzed sulfonamidation of aryl nonafluorobutanesulfonates (aryl nonaflates) is described. A biaryl phosphine ligand, t-BuXPhos, formed the most active catalyst, and K3PO4 in tert-amyl alcohol was found to be the optimal base solvent combination for the reaction. The reaction conditions were tolerant of various functional groups such as cyano, nitro, ester, aldehyde, ketone, chloride, carbamate, and phenol. Heterocyclic aryl nonaflates were found to be suitable coupling partners. High yields of the coupled products were obtained from the reactions between inherently disfavored substrates such as electron-rich nonaflates and electron-poor sulfonamides. Kinetic data suggest reductive elimination to be the rate-limiting step for the reaction. The only limitation of this methodology that we have identified is the inability of 2,6-disubstituted aryl nonaflates to efficiently participate in the reaction.

  DOI：

  10.1021/jo200443u

文献信息

• NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR
  申请人：Shin Song Seok

  公开号：US20130158025A1

  公开（公告）日：2013-06-20

  Disclosed is a novel compound acting as a cannabinoid receptor 1 inhibitor, a prodrug thereof, an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof. The novel compound or the like is useful for preventing or treating diseases mediated by the cannabinoid receptor-1.

  公开的是一种作为大麻素受体1抑制剂的新化合物，其前体，异构体，其药用可接受盐，水合物或溶剂化合物。该新化合物或类似物对预防或治疗由大麻素受体1介导的疾病有用。
• [EN] CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS<br/>[FR] ANTAGONISTES DE CCR5 EN TANT QU'AGENTS THÉRAPEUTIQUES
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2009058919A1

  公开（公告）日：2009-05-07

  The present invention relates to compounds useful in the treatment of CCR5-related diseases and disorders, for example, useful in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).

  本发明涉及在治疗CCR5相关疾病和疾病中有用的化合物，例如，在抑制HIV复制、预防或治疗HIV感染以及治疗由此导致的获得性免疫缺陷综合症（AIDS）方面有用。
• USE OF 4-SUBSTITUTED 1-PHENYLPYRAZOLE-3-CARBOXYLIC ACID DERIVATIVES AS AGENTS AGAINST ABIOTIC PLANT STRESS
  申请人：BAYER INTELLECTUAL PROPERTY GMBH

  公开号：US20140329684A1

  公开（公告）日：2014-11-06

  The invention relates to the use of 4-substituted 1-phenylpyrazole-3-carboxylic acid derivatives of the general formula (I), or salts thereof, where the radicals in the general formula (I) correspond to the definitions given in the description, for enhancing stress tolerance in plants to abiotic stress, for strengthening plant growth and/or for increasing plant yield, and to selected processes for preparing the compounds mentioned above.

  本发明涉及使用4-取代的1-苯基吡唑-3-羧酸衍生物（I）或其盐，其中一般式（I）中的基团对应于描述中给出的定义，用于增强植物对非生物胁迫的耐受性，加强植物生长和/或增加植物产量，并涉及选定的制备上述化合物的过程。
• PROTEIN KINASE INHIBITORS
  申请人：Bearss David J.

  公开号：US20080207632A1

  公开（公告）日：2008-08-28

  Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer, such as Aurora kinase-expressing cancers and Axl kinase-expressing cancers. Compounds of the invention have the following structure: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , X, Z, L 2 and w are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.

  本发明揭示了蛋白激酶抑制剂，其在治疗蛋白激酶介导的疾病和病状中具有功效，例如癌症，如Aurora激酶表达的癌症和Axl激酶表达的癌症。本发明的化合物具有以下结构：包括立体异构体、前药和其药学上可接受的盐，其中R1、R2、R3、X、Z、L2和w如本文所定义。本发明还揭示了含有本发明化合物的组合物，以及与其使用相关的方法。
• Methods for treating Hepatitis C
  申请人：Karp Mitchell Gary

  公开号：US20080096928A9

  公开（公告）日：2008-04-24

  In accordance with the present invention, compounds that inhibit viral replication, preferably Hepatitis C Virus (HCV) replication, have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the treatment or prevention of a viral infection are provided. In another aspect of the invention, compounds useful in the treatment or prevention of HCV infection are provided.

  根据本发明，已经确定了抑制病毒复制的化合物，优选为丙型肝炎病毒（HCV）复制，同时提供了其使用方法。在本发明的一方面，提供了用于治疗或预防病毒感染的化合物。在本发明的另一方面，提供了用于治疗或预防HCV感染的化合物。